Business
Restart Life Sciences Announces Closing First Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement"). Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per...
About this update from Restart Life Sciences Corp.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") announces that further to its news release dated November 12, 2025, the Company has closed the first tranche of its non-brokered private placement for total gross proceeds of CDN$500,000 (the "Placement").","length":406,"tagName":"p"},{"type":"text","content":"Pursuant to the Placement, the Company has allotted and issued 5,000,000 units (the "Units") at a price of CDN$0.10 per Unit. Each Unit consists of one common share and one transferable common share purchase warrant (each, a "Warrant"). Each Warrant entitles the holder to purchase one additional common share for a period of one (1) year at a price of CAD $0.10 per common share.","length":400,"tagName":"p"},{"type":"text","content":"In connection with the Placement, the Company paid cash finder's fees totaling CAD $16,800 and issued 60,000 non-transferable finder warrants (each, a "Finder Warrant") to certain eligible arm's-length finders who introduced subscribers to the Placement. Each Finder Warrant entitles the holder to purchase one common share for a period of one (1) year at a price of CAD $0.10 per common share.","length":412,"tagName":"p"},{"type":"text","content":"The Company intends to use the proceeds from the Offering towards health food trials, potential acquisitions, and general working capital. All securities issued under the Placement are subject to a hold period of four months and one day expiring on April 6, 2026.","length":263,"tagName":"p"},{"type":"text","content":"About Restart Life Sciences Corp. Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.","length":226,"tagName":"p"},{"type":"text","content":"On behalf of the Board of Directors Steve Loutskou Chief Executive Officer, Restart Life Sciences Corp. Tel: +1 (778) 819-0244 Email: [email protected]","length":158,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unk...